Cargando…
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
BACKGROUND: The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in t...
Autores principales: | Toomey, Sinead, Eustace, Alexander J., Fay, Joanna, Sheehan, Katherine M., Carr, Aoife, Milewska, Malgorzata, Madden, Stephen F., Teiserskiene, Ausra, Kay, Elaine W., O’Donovan, Norma, Gallagher, William, Grogan, Liam, Breathnach, Oscar, Walshe, Janice, Kelly, Catherine, Moulton, Brian, Kennedy, M. John, Gullo, Guiseppe, Hill, Arnold D., Power, Colm, Duke, Deirdre, Hambly, Niamh, Crown, John, Hennessy, Bryan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530949/ https://www.ncbi.nlm.nih.gov/pubmed/28750640 http://dx.doi.org/10.1186/s13058-017-0883-9 |
Ejemplares similares
-
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021) -
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
por: Cosgrove, Nicola, et al.
Publicado: (2023) -
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
por: Keegan, Niamh M., et al.
Publicado: (2021) -
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy
por: Gaynor, Nicola, et al.
Publicado: (2023) -
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
por: Coté, Damien, et al.
Publicado: (2018)